Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.

Area of Science:

• Immunology
• Molecular Biology
• Therapeutics

Background:

• Major histocompatibility complex (MHC)-I molecules are crucial for immune surveillance and cancer immunotherapy.
• Classical MHC-I therapies face challenges due to high polymorphism and immune evasion.
• Nonclassical MHC-I molecules present alternative therapeutic avenues with conserved structures and broad immune cell engagement.

Purpose of the Study:

• To review the structural biology, antigen presentation, and immunoregulatory functions of nonclassical MHC-I molecules.
• To explore emerging therapeutic strategies targeting nonclassical MHC-I molecules.
• To provide a framework for developing next-generation immunotherapies.

Main Methods:

• Literature review synthesizing current knowledge on nonclassical MHC-I molecules.
• Analysis of structural biology, antigen presentation pathways, and receptor interactions.
• Evaluation of emerging therapeutic strategies and translational challenges.

Main Results:

• Nonclassical MHC-I molecules (e.g., HLA-E, HLA-F, HLA-G, CD1, MR1) possess limited polymorphism and unique antigen-presenting capabilities.
• These molecules interact with both innate and adaptive immune cells, offering broader therapeutic potential.
• Emerging strategies include immune checkpoint modulation, novel ligands, biologics, vaccines, and cellular therapies.

Conclusions:

• Nonclassical MHC-I molecules represent a promising class of targets for next-generation immunotherapies.
• Understanding their specialized features is key to overcoming limitations of current MHC-I-based treatments.
• Targeting nonclassical MHC-I molecules can enhance the efficacy of treatments for cancers and infectious diseases.